This refers to endometrial safety of Activelle 0.5 mg/ 0.1 mg, which had been insufficiently demonstrated according to the CHMP guideline for HRT products (EMEA/ CHMP/ 021/ 97 rev 1) and this was considered to be of serious public health concern.